About the Authors
- Attila Végh
-
Contributed equally to this work with: Attila Végh, Anita Farkas
Affiliation ImmunoGenes Kft, Budakeszi, Hungary
- Anita Farkas
-
Contributed equally to this work with: Attila Végh, Anita Farkas
Affiliation Department of Immunology, Eötvös Loránd University, Budapest, Hungary
- Dorottya Kövesdi
-
Affiliation Department of Immunology, Eötvös Loránd University, Budapest, Hungary
- Krisztián Papp
-
Affiliation Immunology Research Group, Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary
- Judit Cervenak
-
Affiliation ImmunoGenes Kft, Budakeszi, Hungary
- Zita Schneider
-
Affiliation Department of Immunology, Eötvös Loránd University, Budapest, Hungary
- Balázs Bender
-
Affiliation ImmunoGenes Kft, Budakeszi, Hungary
- László Hiripi
-
Affiliation Agricultural Biotechnology Center, Gödöllő, Hungary
- Glória László
-
Affiliation Department of Immunology, Eötvös Loránd University, Budapest, Hungary
- József Prechl
-
Affiliation Immunology Research Group, Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary
- János Matkó
-
Affiliation Department of Immunology, Eötvös Loránd University, Budapest, Hungary
- Imre Kacskovics
-
* E-mail: ikacsko@elte.hu
Affiliations ImmunoGenes Kft, Budakeszi, Hungary, Department of Immunology, Eötvös Loránd University, Budapest, Hungary
Competing Interests
The authors have read the journal's policy and have the following conflicts: Dr. Végh, Dr. Cervenak and Dr. Bender are scientific researchers; Imre Kacskovics is co-founder and CEO of ImmunoGenes Ltd., Budakeszi, Hungary a company specialized in the generation of FcRn transgenic animals for the production of polyclonal and monoclonal antibodies (these animals are in development phase) (www.immunogenes.com). Eötvös Loránd University, Budapest, Hungary and Agriculture Biotechnology Center, Gödöllő, Hungary have been granted a European patent for this technology (Method using a transgenic animal with enhanced immune response; EP2097444), and seek patent in other major markets. The technology has been licensed exclusively to ImmunoGenes Ltd. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: LH JP JM IK. Performed the experiments: AV AF JC ZS BB. Analyzed the data: DK KP JC GL BB LH. Wrote the paper: IK.